Altimmune

Advancing a Next-Gen Treatment for Obesity & MASH

Class-Leading Lean Mass Preservation Data: Pemvidutide, Altimmune’s GLP-1/Glucagon dual receptor for obesity and MASH has demonstrated lean mass preservation superior to what’s been historically reported with diet and exercise, with a lean loss ratio of only 21.9%, and visceral adipose tissue, a risk factor for cardiovascular disease, reduced by 28.3%.
1:1 Balanced GLP-1 + Glucagon Agonism is a Key Differentiator from Similar MOAs: The glucagon activity in pemvidutide has a direct effect on the liver and is intended to reduce cholesterol, triglycerides, LDL, and liver fat in a more profound way than other incretin-based approaches that also incorporate glucagon but favor GLP-1.
Breakthroughs in Obesity & MASH Clinical Trials: At 48 weeks of treatment in the MOMENTUM trial for obesity, subjects receiving pemvidutide achieved weight loss of up to 15.6% with weight loss continuing at the end of treatment. Additionally, in the IMPACT trial for MASH, subjects achieved up to 68.5% relative reduction in liver fat content, an important predictor of MASH resolution and fibrosis improvement.
Key Events in 2025: Initiation of pivotal Phase 3 obesity program which includes four clinical trials evaluating pemvidutide in a variety of patient populations with obesity, Q2 2025 Phase 2b readout in MASH (IMPACT Trial), Pipeline expansion – 1H 2025 initiation of at least one mid-stage trial evaluating an additional pemvidutide indication.